author-photo

Naoki Niikura

Tokai University

127

Papers

984

Citations

Citation Trend

Filter By

Papers (87) Sort By

Journal Conference Others

persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CLRM-14. OPEN-LABEL, MULTINATIONAL, MULTICENTER, PHASE 3B/4 STUDY OF TRASTUZUMAB DERUXTECAN (T-DXD) IN PATIENTS WITH OR WITHOUT BASELINE BRAIN METASTASIS (BM) WITH PREVIOUSLY TREATED ADVANCED/METASTATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE BREAST CANCER (HER2+ BC): DESTINY-BREAST12

2021
Show All
- Source
- Cite
- Save
Citations (0)
Quantitative Values from Synthetic MRI Correlate with Breast Cancer Subtypes

2021
Show All
- Source
- Cite
- Save
Citations (0)
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.

2021 Breast Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Abstract OT-03-01: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.

2021 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT2-02-09: Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Stability of HER2 Status by Dual-color in Situ Hybridization Before and After Neoadjuvant Chemotherapy in Breast Cancer.

2020 The Tokai journal of experimental and clinical medicine
Show All
- Source
- Cite
- Save
Citations (0)